Practical implication
Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.
The Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance regarding documentation requirements for clinical investigations. This includes clarity on safety data needed for the assessment of medical devices, affecting the processes of clinical safety teams responsible for compiling safety reporting and clinical data for MHRA review.
What changed: The guidance now specifies that documentation for clinical investigation submissions must include comprehensive safety and performance data to meet MHRA assessment requirements.
Why it matters: This update ensures compliance with the UK Medical Device Regulations 2002, impacting the readiness of clinical safety teams to submit accurate and complete safety data, which is essential for the assessment and approval of clinical investigations.
Practical implication: Manufacturers must review and align their safety data compilation processes with the updated MHRA guidance to ensure that all necessary information is included in clinical investigation proposals.
View original source
Published from the Firecrawl policy change extraction pipeline.